Dr. Citrin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Rockville Pike
# 10
Bethesda, MD 20892Phone+1 301-496-5457
Education & Training
- Duke University School of MedicineClass of 2000
Certifications & Licensure
- MD State Medical License 2001 - 2026
- VA State Medical License 2008 - 2026
- American Board of Radiology Radiation Oncology
Clinical Trials
- A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies Start of enrollment: 2007 Feb 01
- An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin Start of enrollment: 2009 Apr 23
- A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum Start of enrollment: 2010 May 24
- Join now to see all
Publications & Presentations
PubMed
- 1516 citationsDurable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer ImmunotherapySteven A. Rosenberg, James Chih-Hsin Yang, Richard M. Sherry, Udai S. Kammula, Michael S. Hughes
Clinical Cancer Research. 2011-07-01 - 50 citationsRecent Developments in Radiotherapy.Deborah E Citrin
The New England Journal of Medicine. 2017-09-14 - 158 citationsInhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice.Jin Pan, Deguan Li, Yanfeng Xu, Junling Zhang, Yueying Wang
International Journal of Radiation Oncology, Biology, Physics. 2017-10-01
Press Mentions
- GE HealthCare Showcases the Latest AI-Enhanced Radiation Therapy Solutions at ASTRO 2024September 26th, 2024
- Alessa Therapeutics Announces IND Clearance for a Study in Collaboration with the National Cancer InstituteJune 7th, 2021
- Can Low-Dose Radiotherapy Treat COVID-19-Related Pneumonia?November 3rd, 2020
Grant Support
- Mechanisms Of Normal Tissue ToxicityNational Cancer Institute2010–2011
- Evaluation Of Novel Radiation ModifiersNational Cancer Institute2010–2011
- Mechanisms Of Normal Tissue ToxicityDivision Of Basic Sciences - Nci2009
- Evaluation Of Novel Radiation ModifiersDivision Of Basic Sciences - Nci2009
- Mechanisms Of Normal Tissue ToxicityNational Cancer Institute2007–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: